Literature DB >> 10745238

Efficacy of influenza vaccination in adult liver transplant recipients.

N M Soesman1, G F Rimmelzwaan, N J Nieuwkoop, W E Beyer, H W Tilanus, M H Kemmeren, H J Metselaar, R A de Man, A D Osterhaus.   

Abstract

To assess the efficacy of influenza vaccination in immunocompromised adult liver transplant (LTx) recipients, the serum antibody responses of 61 of these patients and 35 liver cirrhosis patients with those of 45 of their healthy spouses were compared, after one and two vaccinations with a commercial trivalent subunit influenza vaccine. In addition, virus-specific proliferative T-cell responses were measured in LTx recipients and their healthy spouses. In all three study groups, significant rises in geometric mean antibody titers were observed for all three antigens after one vaccination. These titers did not continue to increase significantly after the second vaccination in patients with cirrhosis and control subjects but did rise for LTx recipients. The overall antibody response to all three influenza virus strains proved to be significantly lower in the LTx recipients than in the group of healthy subjects after both one and two vaccinations. More than 68% of the LTx recipients developed hemagglutination-inhibiting serum antibody titers >/=40 against all three vaccine strains after the first vaccination and more than 80% after the second vaccination. These findings correlated with the T-cell responses determined for the group of LTx recipients and healthy control individuals. Testing of the respective serum samples against influenza virus A/Sydney/5/97, which circulated in the 1997-1998 influenza season and showed a considerable mismatch with the vaccine strain A/Nanchang/933/95, indicated that such a mismatch may have significant consequences for vaccine efficacy, especially for LTx recipients. Collectively the data show that LTx recipients can be vaccinated effectively against influenza despite immunosuppressive therapy. A two-dose vaccination regimen improved vaccination efficacy in LTx recipients. Whether transplant patients generally benefit from a two-dose vaccination regimen should be evaluated further. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10745238

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  26 in total

1.  CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults.

Authors:  Aprille Seidel; David Smith; Edward Yung; Lia Aquino; Tumul Srivastava; Vinod Pullarkat; Ricardo Spielberger; Stephen J Forman; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-08       Impact factor: 5.742

Review 2.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

3.  Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.

Authors:  A Holvast; A Huckriede; J Wilschut; G Horst; J J C De Vries; C A Benne; C G M Kallenberg; M Bijl
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

Review 4.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

Review 5.  The management of patients awaiting liver transplantation.

Authors:  Ka-Kit Li; James Neuberger
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-10-06       Impact factor: 46.802

Review 6.  Effect of a booster dose of influenza vaccine in patients with hemodialysis, peritoneal dialysis and renal transplant recipients: A systematic literature review and meta-analysis.

Authors:  Zhengfa Liao; Xiaojia Xu; Yaping Liang; Yongzhen Xiong; Ruoling Chen; Jindong Ni
Journal:  Hum Vaccin Immunother       Date:  2016-07-08       Impact factor: 3.452

7.  Influenza vaccine immunogenicity in patients with primary central nervous system malignancy.

Authors:  Roy E Strowd; Katrina Swett; Michele Harmon; Annette F Carter; Aurora Pop-Vicas; Michael Chan; Stephen B Tatter; Thomas Ellis; Maria Blevins; Kevin High; Glenn J Lesser
Journal:  Neuro Oncol       Date:  2014-04-08       Impact factor: 12.300

Review 8.  Influenza prevention and treatment in transplant recipients and immunocompromised hosts.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

Review 9.  Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols.

Authors:  Andrea Duchini; John A Goss; Saul Karpen; Paul J Pockros
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Pandemic influenza: implications for programs controlling for HIV infection, tuberculosis, and chronic viral hepatitis.

Authors:  James D Heffelfinger; Pragna Patel; John T Brooks; Helene Calvet; Charles L Daley; Hazel D Dean; Brian R Edlin; Kathleen F Gensheimer; John Jereb; Charlotte K Kent; Jeffrey L Lennox; Janice K Louie; Ruth Lynfield; Philip J Peters; Lauretta Pinckney; Philip Spradling; Andrew C Voetsch; Anthony Fiore
Journal:  Am J Public Health       Date:  2009-10       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.